Exelixis Inc logo

Exelixis Inc

EXEL
Healthcare|Biotechnology|USA
$56.51
-0.60 (-1.05%)
DCF (FCF)
$29.26
Tangible Book
$7.38
Graham Number
$23.55
Earnings Power
$17.69

Upcoming Data Readouts (44)

Aug 2026
Est. completion
P1Neoplasm Malignant
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166n=325
Sep 2026
Est. completion
P2RCC
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
NCT05931393n=18
Sep 2026
Est. completion
P2High Grade Neuroendocrine Neoplasms
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629n=35
Oct 2026
Est. completion
P2Hepatocellular Carcinoma
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04472767n=35
Nov 2026
Est. completion
P1Locally Advanced or Metastatic Solid Tumors
Study of XB010 in Subjects With Solid Tumors
NCT06545331n=396
Dec 2026
Est. completion
P2Metastatic Castration-resistant Prostate Cancer
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06568562n=32
Dec 2026
Est. completion
P2Meningioma
Cabozantinib for Patients With Recurrent or Progressive Meningioma
NCT05425004n=24
Dec 2026
Est. completion
P2Metastatic Renal Cell Carcinoma
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT05263050n=111
Dec 2026
Est. completion
Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
NCT04919122n=468
Dec 2026
Est. completion
P2Hepatocellular Carcinoma
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
NCT06698250n=40
Jan 2027
Est. completion
P2Germ Cell Tumor
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
NCT04876456n=50
Feb 2027
Est. completion
P1P2Metastatic Renal Cell Carcinoma
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT06835972n=43
Feb 2027
Est. completion
P2Metastatic Soft-tissue Sarcoma
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
NCT04551430n=105
May 2027
Est. completion
P2Kidney Cancer
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
NCT04322955n=38
May 2027
Est. completion
P1Solid Tumor
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010n=303
Jun 2027
Est. completion
P1Head and Neck Neoplasms
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
NCT06912087n=36
Jul 2027
Est. completion
P2Malignant Neoplasms of Urinary Tract
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
NCT03541902n=32
Nov 2027
Est. completion
P1Metastatic Renal Cell Carcinoma
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
NCT06132945n=2
Nov 2027
Est. completion
P1Ewing Sarcoma
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
NCT06156410n=30
Nov 2027
Est. completion
P1Solid Tumors
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
NCT07123103n=150

Awaiting Results (18)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026
P2
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Jun 2026
P2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT04413123
May 2026
P3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940
Feb 2026
P2
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
NCT04963283
Jul 2025
P3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
NCT05678673
Jun 2025
P2
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
NCT04289779
Apr 2024
P3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117
Nov 2023
P2
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
NCT04164979
Aug 2023
P2
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
NCT04091750
Feb 2023
P1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960

Recent Press Releases